Advertisement

PRFX

PRF Technologies Ltd.

Healthcare · USD

Set alert

Price alert · PRFX

All alert types
0.73 USD -0.02 -2.68%
As of Oct 30, 2026 Extended hours 0.80 +9.57%
Bid
0.73 × 2
Ask
0.75 × 2
0.71 Day range 0.7421
0.712 52-week range 6.20
YTD
-77.26%
1 year
-87.83%
Open
0.7271
Prev close
0.7502
Mkt cap
2.55M
Vol
58.59K
Avg vol
260.32K
EPS
-4.09
P/E
0.00
Div yield
0.00%
More statistics
Low
0.71
High
0.7421
Forward P/E
-0.37
Beta
0.56
Short ratio
0.02
Inst. own
6.57%
Dividend
0.00
Ex-div date
Earnings
Feb 29, 2024
50-d avg
1.84
200-d avg
3.57
1y target
0.00

2Y chart

Chart tools
Interval
PRFX two-year price chart0.6921.341.962.583.2Oct 24Mar 25Aug 25Jan 26Jun 26Oct 26

Key statistics

Market cap
3.90M
Enterprise value
339.62K
Trailing P/E
0.00
Forward P/E
-0.37
PEG ratio
0.00
Price / sales
0.00
Price / book
0.00
EPS (TTM)
-147.36
Beta
0.56
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
-4.93M
Total cash
2.78M
Total debt
59.00K
Return on equity
-716.67%
Shares outstanding
874.86K
Short % of float
9.08%
50-day average
1.84
200-day average
3.57

Analyst view

Consensus: none

Price target (mean) 0.00
Ratings (0m) 1 0 buy · 1 hold · 0 sell
  • Strong buy0
  • Buy0
  • Hold1
  • Sell0
  • Strong sell0

Next earnings

Feb 29, 2024

Expected Feb 29, 2024. Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
PRFX Revenue — quarterly 0
2021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 2024
PRFX Net income — quarterly -7.31M
2021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 2024
PRFX EPS — quarterly 10.00
2021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 2024

Earnings

PRFX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Aug 15, 2024Jun 1, 20240.00-9.60——
May 15, 2024Mar 1, 20240.00-65.27——
Feb 29, 2024Dec 1, 20230.00———
Nov 15, 2023Sep 1, 20230.0011.52——
May 15, 2023Mar 1, 20230.00-52.79——
Mar 16, 2023Dec 1, 20220.00-69.59——

Upgrades / downgrades

PRFX analyst upgrades and downgrades
DateFirmActionFromTo
Oct 24, 2024Maxim GroupdownBuyHold
Jun 26, 2024Maxim GroupreitBuyBuy

About PRF Technologies Ltd.

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
Israel

News

Your note

Sign in to keep a note on PRFX — it syncs with the Stock Master app.

Institution ownership

PRFX institution ownership
Holder% heldSharesValueReported
UBS Group AG0.74%6,49628.97KSep 29, 2024
Two Sigma Securities, LLC0.49%4,30819.21KSep 29, 2024
HRT Financial LP0.41%3,57715.95KSep 29, 2024
Osaic Holdings Inc0.02%192856Sep 29, 2024

Fund ownership

PRFX fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.01%80356Sep 29, 2024
Advertisement